 | • レポートコード：MRC2304F038 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本市場調査資料では、世界の薬物乱用治療市場規模が、2021年に5,877.28百万ドル、2022年に6,432.51百万ドルになり、その後CAGR 9.71％で成長して2027年までに10,252.42百万ドルに達すると予測しています。本書は、薬物乱用治療の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物乱用タイプ別分析（アルコール中毒、コカイン、マリファナ、ニコチン中毒）、製品別分析（行動療法、医薬品）、治療オプション別分析（グループカウンセリング、入院治療、個別薬物カウンセリング、長期居住型療養施設、外来治療プログラム）、流通チャネル別分析（病院薬局、小売薬局＆ドラッグストア）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、本書内の企業情報には、AbbVie Inc.、Accord Healthcare Limited、Alkermes PLC、Amphastar Pharmaceuticals, Inc.、BioCorRx, Inc.、Cipla Limited、Dr. Reddy’s Laboratories Ltd.、Elite Pharmaceuticals, Inc.、GlaxoSmithKline PLC、Glenmark Pharmaceuticals Limited、Indiviorなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の薬物乱用治療市場規模：薬物乱用タイプ別 - アルコール中毒の市場規模 - コカインの市場規模 - マリファナの市場規模 - ニコチン中毒の市場規模 ・世界の薬物乱用治療市場規模：製品別 - 行動療法の市場規模 - 医薬品の市場規模 ・世界の薬物乱用治療市場規模：治療オプション別 - グループカウンセリングの市場規模 - 入院治療の市場規模 - 個別薬物カウンセリングの市場規模 - 長期居住型療養施設の市場規模 - 外来治療プログラムの市場規模 ・世界の薬物乱用治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局＆ドラッグストアチャネルの市場規模 ・世界の薬物乱用治療市場規模：地域別 - 南北アメリカの薬物乱用治療市場規模 アメリカの薬物乱用治療市場規模 カナダの薬物乱用治療市場規模 ブラジルの薬物乱用治療市場規模 ... - アジア太平洋の薬物乱用治療市場規模 日本の薬物乱用治療市場規模 中国の薬物乱用治療市場規模 インドの薬物乱用治療市場規模 韓国の薬物乱用治療市場規模 台湾の薬物乱用治療市場規模 ... - ヨーロッパ/中東/アフリカの薬物乱用治療市場規模 イギリスの薬物乱用治療市場規模 ドイツの薬物乱用治療市場規模 フランスの薬物乱用治療市場規模 ロシアの薬物乱用治療市場規模 ... - その他地域の薬物乱用治療市場規模 ・競争状況 ・企業情報 |
The Global Substance Abuse Treatment Market size was estimated at USD 5,877.28 million in 2021 and expected to reach USD 6,432.51 million in 2022, and is projected to grow at a CAGR 9.71% to reach USD 10,252.42 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Substance Abuse Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Substance Abuse Type, the market was studied across Alcohol Addiction, Cocaine, Marijuana, and Nicotine Addiction.
Based on Product, the market was studied across Behavioral Treatment and Drugs. The Drugs is further studied across Acamprosate, Buprenorphine, Bupropion, Disulfiram, Methadone, Naltrexone, and Varenicline.
Based on Treatment Option, the market was studied across Group Counseling, In-patient Treatment, Individualized Drug Counseling, Long-Term Residential Treatment, Outpatient Treatment Programs, and Short-Term Residential Treatment.
Based on Distribution Channel, the market was studied across Hospital Pharmacies and Retail Pharmacies & Drug Stores.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Substance Abuse Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Substance Abuse Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Substance Abuse Treatment Market, including AbbVie Inc., Accord Healthcare Limited, Alkermes PLC, Amphastar Pharmaceuticals, Inc., BioCorRx, Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Elite Pharmaceuticals, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Indivior, LFB Group, Mallinckrodt LLC, Novartis International AG, Pfizer Inc., Purdue Pharma L.P., Reckitt Benckiser Group PLC, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Viatris Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Substance Abuse Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Substance Abuse Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Substance Abuse Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Substance Abuse Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Substance Abuse Treatment Market?
6. What is the market share of the leading vendors in the Global Substance Abuse Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Substance Abuse Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing cases of tobacco addiction across the globe
5.1.1.2. Increasing patient awareness and higher treatment seeking rate
5.1.1.3. Favorable efforts from the governments to curb the use of these substances
5.1.2. Restraints
5.1.2.1. Relatively high cost of the treatment and poor treatment compliance
5.1.3. Opportunities
5.1.3.1. Emerging number of treatment centers with partnerships with private recovery facilities
5.1.3.2. Growing introduction of new products and therapy coupled with better reimbursement options
5.1.4. Challenges
5.1.4.1. Increasing cases of discontinuation of behavioral therapies and patients opt for outpatient care
5.2. Cumulative Impact of COVID-19
6. Substance Abuse Treatment Market, by Substance Abuse Type
6.1. Introduction
6.2. Alcohol Addiction
6.3. Cocaine
6.4. Marijuana
6.5. Nicotine Addiction
7. Substance Abuse Treatment Market, by Product
7.1. Introduction
7.2. Behavioral Treatment
7.3. Drugs
7.4.1. Acamprosate
7.4.2. Buprenorphine
7.4.3. Bupropion
7.4.4. Disulfiram
7.4.5. Methadone
7.4.6. Naltrexone
7.4.7. Varenicline
8. Substance Abuse Treatment Market, by Treatment Option
8.1. Introduction
8.2. Group Counseling
8.3. In-patient Treatment
8.4. Individualized Drug Counseling
8.5. Long-Term Residential Treatment
8.6. Outpatient Treatment Programs
8.7. Short-Term Residential Treatment
9. Substance Abuse Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies & Drug Stores
10. Americas Substance Abuse Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Substance Abuse Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Substance Abuse Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Accord Healthcare Limited
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Alkermes PLC
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Amphastar Pharmaceuticals, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BioCorRx, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Cipla Limited
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Dr. Reddy’s Laboratories Ltd.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Elite Pharmaceuticals, Inc.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. GlaxoSmithKline PLC
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Glenmark Pharmaceuticals Limited
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Indivior
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. LFB Group
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Mallinckrodt LLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Novartis International AG
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Pfizer Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Purdue Pharma L.P.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Reckitt Benckiser Group PLC
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Sanofi S.A.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Teva Pharmaceutical Industries Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Viatris Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing